Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Retained Earnings (2023 - 2025)

Historic Retained Earnings for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$337.7 million.

  • CG Oncology's Retained Earnings fell 8136.41% to -$337.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$337.7 million, marking a year-over-year decrease of 8136.41%. This contributed to the annual value of -$218.0 million for FY2024, which is 6775.25% down from last year.
  • CG Oncology's Retained Earnings amounted to -$337.7 million in Q3 2025, which was down 8136.41% from -$293.9 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Retained Earnings peaked at -$129.9 million during Q4 2023, and registered a low of -$337.7 million during Q3 2025.
  • Its 3-year average for Retained Earnings is -$216.4 million, with a median of -$202.1 million in 2024.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 6775.25% in 2024, then tumbled by 8136.41% in 2025.
  • Over the past 3 years, CG Oncology's Retained Earnings (Quarter) stood at -$129.9 million in 2023, then plummeted by 67.75% to -$218.0 million in 2024, then plummeted by 54.92% to -$337.7 million in 2025.
  • Its Retained Earnings was -$337.7 million in Q3 2025, compared to -$293.9 million in Q2 2025 and -$252.4 million in Q1 2025.